The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

I last covered DexCom (NASDAQ:DXCM) over 1 year ago, when the company's stock price had collapsed from a then all-time peak of $290 to $191, during the market selloff in response to the onset of the ...

Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

In 2020, Dexcom recorded a new high of $1.9 billion in revenue, prompting CEO Kevin Sayer to declare it the diabetes devicemaker’s “best year ever.” The company then proceeded to outstrip that total ...

Revenue for Q4 2024 was $1.114 billion, marking an 8% increase year-over-year. Non-GAAP EPS stood at $0.45, missing the estimated $0.50 and reflecting a 10% decline from Q4 2023. Operating income (non ...